ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2022

Diagnostic and Prognostic VALUE of Salivary GLAND Ultrasonography in Primary Sjögren’s Syndrome:  a Preliminary Study

Maria Pascual1, Mercè López1, Joan Miquel Nolla2, Javier Narváez3, helena borrell1 and Carmen Moragues4, 1DEPARMENT OF RHEUMATOLOGY, HOSPITAL UNIVERSITARI DE BELLVITGE, BARCELONA, Spain, 2Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, 3Rheumatology Department, Hospital de Bellvitge. Barcelona. Spain, L’Hospitalet de Llobregat, Spain, 4DEPARMENT OF RHEUMATOLOGY, HOSPITAL UNIVERSITARI DE BELLVITGE, barc+, Spain

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Diagnostic imaging, prognostic factors, salivary gland and ultrasonography, Sjogren's syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 7, 2017

Title: Imaging of Rheumatic Diseases Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

In recent years, salivary gland ultrasonography (SGUS) has emerged as a promising tool for the diagnosis and prognostic stratification of patiens with primary Sjögren’s syndrome. However, more studies are needed to demostrate its diagnostic usefulness before it can be used in daily clinical practice. Our objective is to evaluate the diagnostic and prognostic value of salivary gland ultrasonography (SGUS) in primary Sjögren’s syndrome (pSS).

Methods:

Patients with primary SS (fulfilling the American-European Consensus Group criteria of 2002) and controls with secondary SS or sicca syndrome are evaluated using a simplified SGUS scoring system.

Parotid and submandibular glands on both sides were assessed for parenchymal inhomogeneity, which was perfomed by the same ecographist. Echostructural alterations of the salivary glands were graded form 0 to 3, with grades 0 (normal) and 1 (mild inhomogeneity) being interpreted as normal, and grades 2 and 3 as primary SS typical lesions. Associations between SGUS and clinical and laboratory disease were analyzed. Moreover, to test the accuracy for diagnosis of SGUS, we calculated sensitivity, specificity, PPV, NPV and positive/negative likehood ratio.

Results:

Thus far, twenty-five patients have been included, thirteen with pSS and twelve with secondary SS/sicca syndrome. The hypoechoic lesions (score 2 or 3) were found in 76.9% of primary SS patients and in none of controls (p <0.001). Specificity and positive predictive value of abnormal SGUS was 100%, sensitivity and negative predictive values were 76.9% and 80%, respectively. The negative likehood ratio was 0.23 and the positive likehood ratio was > 10, which means that typical SS lesions would improve the probability of having primary SS. However, if the SGUS results negative, another diagnostic test are needed in order to avoide patient misclassification.

Patients with parenchimal heterogeneity, more frequently, had positivity for anti-Ro/SSA (p=0.022), anti-La/SSB (p=0.005) and rheumatoid factor (p=0.007). Moreover, the presence of hypergammaglobulinemia, (p=0.001), leucolymphopenia (p<0.001), and elevated ESR (p<0.001) was associated with typical pathologic SGUS. Consequently, the EULAR Sjögren’s syndrome disease activity index (ESSDAI) was higher in patients with abnormal SGUS (p=0.025). We could not detect an association with age, disease duration, ANA positivity, complement level, anemia and, suprinsingly, extraglandular involvement.

Conclusion:

In our preliminary study, assessment of parenchyma dyshomogeneity with SGUS is highly specific in differentiating primary SS from idiopathic sicca syndrome or Secondary SS. Moreover, this technic can provide prognostic stratification in patients with primary SS.


Disclosure: M. Pascual, None; M. López, None; J. M. Nolla, None; J. Narváez, None; H. borrell, None; C. Moragues, None.

To cite this abstract in AMA style:

Pascual M, López M, Nolla JM, Narváez J, borrell H, Moragues C. Diagnostic and Prognostic VALUE of Salivary GLAND Ultrasonography in Primary Sjögren’s Syndrome:  a Preliminary Study [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/diagnostic-and-prognostic-value-of-salivary-gland-ultrasonography-in-primary-sjogrens-syndrome-a-preliminary-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/diagnostic-and-prognostic-value-of-salivary-gland-ultrasonography-in-primary-sjogrens-syndrome-a-preliminary-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology